Anticoagulation regimens for thalidomide and lenalidomide.
Zangari
Maurizio
M
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA.
D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D012307:Risk Factors; D013792:Thalidomide / Q000009:adverse effects* / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000188:drug therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D013792:Thalidomide; D000077269:Lenalidomide